Q-omics provides the consensus-scored COX20P2 profile across patient tissues and cancer cell-line models. COX20P2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, COX20P2 is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, COX20P2 RNA expression shows 8,390 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, LUAD, and BRCA as cancer lineages where COX20P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX20P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX20P2 survival associations across molecular data types. COX20P2 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX20P2 RNA expression–survival associations across cancer types. High COX20P2 expression shows unfavorable associations in LGG, LUAD, LIHC and MESO, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for COX20P2 RNA expression.
This table summarizes COX20P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for COX20P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX20P2 shows higher tumor expression in LUAD, UCEC, THCA, LUSC and LIHC. The LUAD box plot shows higher COX20P2 RNA expression in tumor versus normal tissue (log2 FC = +0.285, t-test p = .006).
This table shows molecular features associated with COX20P2 in patient tissues and cancer cell lines. In patient samples, COX20P2 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
